+44 7868 792050
China Pharmaceutical University, China
Posters & Accepted Abstracts: J Clin Exp Dermatol Res
Vitiligo is a kind of skin depigmentation disorder which pathological mechanism is still unclear. There was less progress in the drug treatment of vitiligo within decades due to the unidentified pathological mechanism and therapeutic target. We found that butin, a new kind of small molecule compound derived from herb treated vitiligo, which could regulate the pigmentation process in melanoma cells and organ-cultured human skin. For further study the targets of the butin, we synthesized a novel fluorescent butin- BODIPY, which could improve melanogenesis in B16F10 cell line by selectively binding to its endoplasmic reticulum; we employed the proteomic approach of isobaric tags for relative and absolute quantification (iTRAQ), followed by LC-MS/MS, using the organcultured human skin with or without butin as a model. In total, 4550 unique proteins were identified. Of those, 60 were up-regulated and 242 down-regulated after 48 hours treatment with butein (10 �?¼M). The study aims at discovering therapeutic target of vitiligo and focus on the new mechanism of butin.
Jinpeng Lv is currently pursuing Doctorate in Pharmacology in China Pharmaceutical University, China. His main research is therapeutic target of vitiligo and proteomic.